Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now     
Bio B2B 〉Panion & BF Biotech Inc.

Panion & BF Biotech Inc.

Chat Now My Favorites
Introduction
Established in 1976, Panion & BF Biotech (PBF) is a company specialized in the manufacturing of pharmaceutical products With its diligent effort to seek business transformation, upgrade and expansion over the past years, PBF is now a well-established international biopharmaceutical company specialized in diversified operations, including new drug development, drug manufacturing, cosmeceutical/nutraceuticals, infection control, and diagnostics. PBF pursues constant innovation and outstanding quality and has obtained PIC/S GMP and Cosmetic GMP national certification. Nephoxil®, an important, patented drug developed by PBF, has now successfully completed its international clinical trial and launched on the global market. With its insightful global perspective, PBF has established a solid foundation for its operations in Taiwan and development on the international market. PBF looks forward to sharing its success in multi-faceted R&D with everyone across the globe and fulfilling its corporate vision of “Bringing Better Health and Beautiful Life to the World”.

PBF Business Sectors
1. PBF Pharmaceuticals (New Drug Development & Niche Generic Drug)
Dermatology, nephrology, urology and general
2. PBF Cosmeceuticals & Nutraceuticals
Skin, hair, body and physical health
3. PBF Hygienic
Hospital line, animals & pets and lifestyle
4. PBF Diagnosis
Infection IVD and tumor biomarker

Our Achievements in New Drug Development
1. Nephoxil®: The global New Drug Indicated for the treatment of  hyperphosphatemia in Chronic Kidney Disease (CKD) Patients
2. 1st NCE developed by Taiwanese pharmaceutical company
3. Successfully completed global clinical trials (1800+ patients, 19 clinical trials worldwide)
4. The only dual effects phosphate binder on the market:
5. Serum Phosphate control + Anemia Amelioration
6. Successful Worldwide Licensing & Collaboration
7. US, Europe: Keryx Biopharmaceuticals
8. Japan: Japan Tobacco / Torii Pharmaceutical
9. China: Weigao Pharmaceutical

National Awards & Recognitions
2003  National Biotechnology Award
2005  Taipei Biotech Award
2005  Award of Drug Development – R&D Innovations
2005  Award of Drug Development – Manufacturing
2005  Symbol of National Quality
2006  6th OEMA Outstanding Enterprise Award
2006  MOEA Outstanding ITDP Award
2007  15th Industrial Technology Advancement Award
2010  Awarded MOEA DOIT Grants
2013 10th National Innovation Award
 
Introduction
Established in 1976, Panion & BF Biotech (PBF) is a company specialized in the manufacturing of pharmaceutical products With its diligent effort to seek business transformation, upgrade and expansion over the past years, PBF is now a well-established international biopharmaceutical company specialized in diversified operations, including new drug development, drug manufacturing, cosmeceutical/nutraceuticals, infection control, and diagnostics. PBF pursues constant innovation and outstanding quality and has obtained PIC/S GMP and Cosmetic GMP national certification. Nephoxil®, an important, patented drug developed by PBF, has now successfully completed its international clinical trial and launched on the global market. With its insightful global perspective, PBF has established a solid foundation for its operations in Taiwan and development on the international market. PBF looks forward to sharing its success in multi-faceted R&D with everyone across the globe and fulfilling its corporate vision of “Bringing Better Health and Beautiful Life to the World”.

PBF Business Sectors
1. PBF Pharmaceuticals (New Drug Development & Niche Generic Drug)
Dermatology, nephrology, urology and general
2. PBF Cosmeceuticals & Nutraceuticals
Skin, hair, body and physical health
3. PBF Hygienic
Hospital line, animals & pets and lifestyle
4. PBF Diagnosis
Infection IVD and tumor biomarker

Our Achievements in New Drug Development
1. Nephoxil®: The global New Drug Indicated for the treatment of  hyperphosphatemia in Chronic Kidney Disease (CKD) Patients
2. 1st NCE developed by Taiwanese pharmaceutical company
3. Successfully completed global clinical trials (1800+ patients, 19 clinical trials worldwide)
4. The only dual effects phosphate binder on the market:
5. Serum Phosphate control + Anemia Amelioration
6. Successful Worldwide Licensing & Collaboration
7. US, Europe: Keryx Biopharmaceuticals
8. Japan: Japan Tobacco / Torii Pharmaceutical
9. China: Weigao Pharmaceutical

National Awards & Recognitions
2003  National Biotechnology Award
2005  Taipei Biotech Award
2005  Award of Drug Development – R&D Innovations
2005  Award of Drug Development – Manufacturing
2005  Symbol of National Quality
2006  6th OEMA Outstanding Enterprise Award
2006  MOEA Outstanding ITDP Award
2007  15th Industrial Technology Advancement Award
2010  Awarded MOEA DOIT Grants
2013 10th National Innovation Award
 
  Video